DarioHealth FY26 Q2 net loss narrows 39% to $7.92 million; revenue falls 3.6% to $5.18 million
DRIO•Expense trends
- R&D expense dropped 43.6% to $2.1 million, reflecting post-merger integration efficiencies and AI-driven headcount reductions.
Quarterly results
- DarioHealth posted a GAAP net loss of $7.92 million, narrowing 39% from the year-earlier quarter.
- Revenue fell 3.6% to $5.18 million, pressured by lower pharma-channel revenue tied to a prior-year non-recurring item.
- GAAP gross margin rose 6.5 percentage points to 61.7%, helped by lower technology amortization, lower hosting costs, and an IEEPA tariff refund.
Commercial updates
- DarioHealth said it had 181 customers at quarter-end.
- The company also cited a Fortune 50 employer award covering 100,000+ eligible employees and a GLP-1 program launch.
